Recent Expansions in an Emergent Novel Drug Delivery Technology: Emulgel.

Rungta College of Pharmaceutical Sciences and Research, Kohka- Kurud Road, Bhilai, Chhattisgarh, India. Electronic address: .
Journal of Controlled Release (Impact Factor: 7.63). 07/2013; DOI: 10.1016/j.jconrel.2013.06.030
Source: PubMed

ABSTRACT Emulgel is an emerging topical drug delivery system to which if more effort is paid towards its formulation & development with more number of topically effective drugs it will prove a boon for derma care & cosmetology. Emulgels are either emulsion of oil in water or water in oil type, which is gelled by mixing it with gelling agent. Incorporation of emulsion into gel increases its stability & makes it a dual control release system. Due to lack of excess oily bases & insoluble excipients, it shows better drug release as compared to other topical drug delivery system. Presence of gel phase makes it a non greasy & favors good patient compliance. These reviews gives knowledge about Emulgel including its properties, advantages, formulation considerations, and its recent advances in research field. All factors such as selection of gelling agent, oil agent, emulsifiers influencing the stability and efficacy of Emulgel are discussed. All justifications are described in accordance with the research work carried out by various scientists. These brief reviews on formulation method has been included. Current researched that work carried out on Emulgel are also discussed and highlighted the wide utility of Emulgel in topical drug delivery system. After the vast study, it can be concluded that the Emulgels appear better & effective drug delivery system as compared to other topical drug delivery system. The comprehensive analysis of rheological and release properties will provide an insight into the potential usage of Emulgel formulation as drug delivery system.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: The efficacy of ophthalmic semi-solid hydrogels is mostly based on an increase of ocular residence time, via enhanced viscosity and mucoadhesive properties. Preformed and in particular in situ gelling systems improve bioavailability and decrease the side effects induced by the systemic absorption of topically applied ophthalmic drugs. Since increased viscosity often causes the discomfort of blurred vision and foreign body sensation, it is important to assess the optimal range of viscosity as well as the most suitable rheological behavior which will ensure good efficacy and tolerance.
    Advanced Drug Delivery Reviews. 01/1995;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to develop and evaluate topical formulations of Spantide II, a neurokinin-1 receptor (NK-1R) antagonist, for the treatment of inflammatory skin disorders. Spantide II lotion and gel was formulated with and without n-methyl-2-pyrrolidone (NMP) as a penetration enhancer. The release of Spantide II from gels was evaluated using microporous polyethylene and polypropylene membranes in a Franz Diffusion cell setup. In vitro percutaneous absorption of Spantide II from lotion and gel formulations was evaluated using the above setup by replacing the membranes with hairless rat skin. The in vivo anti-inflammatory activity of Spantide II formulations was evaluated in an allergic contact dermatitis (ACD) mouse model. Among different gels studied, PF127 gel showed highest (70-fold) release of Spantide II compared with hydroxypropyl methylcellulose (HPMC) and hydroxypropyl cellulose (HPC) gels. Lotion and gel formulations with or without NMP showed no detectable levels of Spantide II in the receiver compartment of the Franz diffusion cell until 24 hours. However, Spantide II showed significant retention in epidermis and dermis from lotion and gel formulations at 24 hours. The dermal levels increased approximately 3.5- and 2-fold when the lotion and gel formulations contained NMP as compared with the formulation with no NMP (P < .05). The in vivo studies indicated that Spantide II formulations with NMP were effective in significantly reducing ACD response, similar to dexamethasone (0.5 mM). In conclusion, Spantide II was stable as a topical formulation and delivered to target skin tissue (epidermis and dermis) for the treatment of ACD. In addition this study supports the role of cutaneous neurosensory system in modulating inflammatory responses in the skin.
    AAPS PharmSciTech 02/2005; 6(4):E565-72. · 1.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pharmacotherapeutics has begun to play an increasingly important role in the management of patients with neovascular age-related macular degeneration (AMD). Because micro- and nano-particulates are currently being evaluated as a potential drug-delivery option for AMD patients, the purpose of this analysis was to describe how micro- and nano-particulates have been used experimentally and what their potential clinical applications may be. Micro- and nano-particulates have been used primarily on a pre-clinical basis as new drug-delivery devices in experimental models of neovascular AMD. It is likely that micro- and nano-particulates will become an important component of targeted clinical pharmacotherapeutics in patients with neovascular AMD.
    Advanced Drug Delivery Reviews 01/2006; 57(14):2047-52. · 12.89 Impact Factor